Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by… Continue reading Mucosis receives financial support from the dutch government for its FluGEM program
Author: Willem van Lawick
Pronota presents foundation of Next Generation Sequencing application to identify and quantify proteins.
Ghent, Belgium, 19th May 2010 – Pronota, the Belgian developer of protein biomarker diagnostics, announced today its successful proof of concept of a novel, diagnostic platform. The company reports the first Next Generation Sequencing (NGS) application to identify and quantify proteins.
Pronota raises an additional EUR 1.5 million in a final close of its Series B financing totaling EUR 7.9 million
Ghent, Belgium, 17th May 2010 – Pronota NV today announced that it has raised an additional EUR 1.5 million in the final close of its Series B financing. The financing has been subscribed by MedSciences Capital, the venture capital arm of Kempen & Co, which is a specialized Dutch merchant bank. Pronota has raised a… Continue reading Pronota raises an additional EUR 1.5 million in a final close of its Series B financing totaling EUR 7.9 million
Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality – FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality
Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants. ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor. The two year follow up data from the phase I/II study show no Transplant Related Mortality… Continue reading Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality – FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality
Mucosis appoints Dr. Roberto Grimandi as chief medical officer
Dutch vaccine development company MUCOSIS B.V. announced today that Dr. Roberto Grimaldi, MD was appointed Chief Medical Officer at Mucosis. Dr. Grimaldi is an accomplished executive and consultant to the vaccine industry who brings over 25 years of experience. As an expert on vaccine development he will lead the Mucosis development programs into clinical trials… Continue reading Mucosis appoints Dr. Roberto Grimandi as chief medical officer
